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Ittununomodulatory effects of retinoids may be part of 
their anti-carcinogenic and anti-inflammatory prop-
erties. We studied the in vivo effects of retinoic acid 
(&A) on antigen-presenting activity of human epider-
lUal Langerhans cells and on accessory cell activity of 
keratinocytes. Two skin sites from each volunteer were 
treated in vivo with 0.1% RA or vehicle, respectively, 
once a day for 4 d. RA-treated epidermal cell (RA-EC) 
alloantigen presentation to CD4+ T cells in each vol-
unteer tested was consistently greater than that in-
duced by vehicle EC. However, this increased antigen-
presenting activity did not lead to autoreactive CD4+ 
T -lymphocyte proliferation. Elevated unfractionated 
epidermal antigen-presenting activity of RA-EC was 
not due to increased keratinocyte major histocompati-
bility complex (MHC) or intercellular adhesion mole-
cule expression or to other keratinocyte accessory 
signaling, because incubation o~ CD1a- flou~os~e~ce­
activated cell sorter (FACS)-purtfied RA-EC lDhlblted 
alloantigen presentation, presumably through in-
creased keratinocyte transforming growth factor-po 
By contrast, Langerhans cell function was upregu-
A lthough the immunomodulatory effects of retinoids are not well defined [1 -4], the beneficial anti-carci-nogenic properties of retinoids [5 - 7] may be attrib-uted in part to modulation of the host tumor Immune response [8] . Similarly, modulation of the .human 
anti-papilloma virus immune response [9] ~a~ be a mec~al1lsm un-
derlying the beneficial clinical effect of ret1l10~ds 111 treat1l1g bem~n 
and precancerous viral papillomas of the shn, larynx, or cervix 
[10-12]. 
Cellular immune responses in the skin are initiated by presenta-
tion of antigen to antigen-specific T cells by cutaneous Langerhans 
cells (LC) [13] . Like murine LC, human epidermal LC function as 
potent antigen-presenting cells for a variety of T-cell-dependent 
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lated; FACS-purified CDla+ Langerhans cells derived 
from RA-EC displayed a markedly increased ability, 
relative to Langerhans cells from vehicle EC, to 
present alloantigen to T cells. Triple color flow-cyto-
metric analysis ofRA-EC and vehicle EC suspensions 
revealed that RA treatment did not modify the num-
ber of DR + and CD la+DR + EC, but did result in statis-
tically significant increases in Langerhans cells expres-
sion of HLA-DR, CD11c, and CDlc. Another novel 
finding was that HLA-DR-dependent Langerhans 
cells antigen-presenting activity in both normal and 
RA-treated skin was completely blocked by anti-
CD11c antibody. Thus, retinoid upregulation of anti-
gen-presenting activity may be due to upregulation of 
Langerhans cell CD11c, as well as class II MHC. Up-
regulation of cutaneous immune responsiveness in 
human skin without autoreactivity has not (to our 
knowledge) been reported previously, and the Langer-
hans cell phenotypic and functional state achieved is 
distinct from previously reported states of Langer hans 
cell activation.] Invest Dermato1103:775 -779, 1994 
immune responses to haptens and antigens [14,15]. We postulated 
that topically administered retinoids may modulate the antigen-
presenting activity of epidermis, either as a direct effect on LC or as 
an indirect effect on keratinocytes. 
Therefore, we assessed the i/1 lI illo effects of retinoic acid (RA) on 
the antigen-presenting activity of human epidermal LC and on the 
antigen-presenting accessory cell activity of keratinocytes. hI lIillO, 
RA treatment of human skin upregulated critical antigen-present-
ing cell molecules on LC, such as CDl1c and HLA-DR, resulting in 
an increased immunologic LC functional activity. This occurred 
without induction of auto reactivity, possibly because of a concomi-
tant increase of keratinocyte inhibition of antigen-presenting activ-
ity. Selective upregulation of human immunologic molecules and 
cells of dendritic antigen-presenting cell lineage may be of rele-
vance to clinical states in which immune stimulation by LC may be 
beneficial. 
MATERIALS AND METHODS 
Subjects Two sites from each vol unteer were treated ill "ivowith 0.1 % RA 
(R. W . Johnson Pharmaceutical Research Institute, Raritan, NJ) dissolved 
into a vehicle composed of 70% ethanol and 30% propylene glycol or with 
the ethanoljpropylene glycol vehicle alone, respectively, once a day for 4 d, 
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at which time keratome biopsies were performed. After each application, the 
treated sites were covered with a semiocclusive plastic wrap (Telfa-Pad). 
None of the volunteers (male/female ratio = 5: 4) displayed redness or irri-
tation with this treatment, in contrast to RA application under full occlusion 
[16]. 
Antibodies The panel of monoclonal antibodies employed is as follows: 
anti - HLA-DR (Becton Dickinson, Mountain View, CAl, anti-CDla (Bec-
ton Dickinson), anti-CDlb and CDlc (Amac, Westbrook, ME), OKMl 
(Ortho, Raritan, NJ), Leu M5 (Becton Dickinson), anti-CDlla (Amac), 
anti-HLA-l (Atlantic Antibodies), OKM5 (Ortho), Leu M3 (Becton Dick-
inson), anti-CD54 (Amac), anti-HPCA-l (Becton Dickinson), anti-Fclg-
GRII (Medarex, West Lebanon, NH), and anti-FcIgGRl (Medarex). Poly-
clonal antibodies included fluorescein isothiocyanate (FITC)-conjugated 
goat anti-mouse immunoglobulin (Ig)Gl (Boehringer, Indianapolis, IN) 
and phycoerythrin (PE) goat anti-mouse IgG2b (Cal tag, South San Fran-
cisco, CAl. Streptavidin conjugated with allophycocyanin (APe) was pur-
chased from Biomeda (Foster City, CAl · 
Flow-Cytometrie Analysis Epidermal suspensions, prepared as de-
scribed previously [17], were FcIgGR-blocked with purified heat-aggre-
gated (65 'C, 20 min) human IgG (Sigma Chemical) at a concentration of 
0.5 mg/ml for 30 min at 4'C and triple stained as described previously [17]. 
Flow cytometry was performed using an Epics Elite (Coulter Cytometry, 
Hialeah, FL). Signals for log forward light scatter (LFLS) and log 90' light 
scatter (L90LS), as well as fluorescence from FITC, PE, and APC were 
collected on a four-decade logarithmic scale (LFITC, LPE, LAPC), as de-
scribed previously. 
Based upon isorype control values, HLA-DR+ or CD1a+ epidermal cells 
(EC) were electronically selected from single-parameter histograms of cell 
counts at each level of APC or FITC fluorescence intensity, respectively. 
The selected cells were then analyzed on two additional histogram parame-
ters, such as LFITC versus LPE, to determine isorype background and spe-
cific staining intensities on LC themselves, in the absence of contaminating 
autofluorescent keratinocytes. The mean fluorescence intensity of particular 
markers was determined by subtracting the nonspecific background (isotype 
controls) from the fluorescence intensity of cells stained with specific mono-
clonal antibodies. Fluorescence index (FI) of a surface marker on a subset 
population was defined as the ratio of mean fluorescence intensity of the 
specific antibody to mean fluorescence intensity on that specific subset 
stained with the isotype control. The percent of cells expressing a given 
marker was determined as the number of cells within a given area of a 
histogram displaying positive staining with the isotype control antibody 
subtracted from the number of cells within the same area of the histogram 
displaying positive staining with the specific marker. 
Functional Assessment of Alloantigen-Presenting Capacity of 
EC Eighty thousand EC were mixed with 50,000 allogeneic CD4+ T 
lymphocytes (prepared by negative selection in round-bottom microtiter 
wells for 7d) to assess [3H]Tdr (ICN Radiochemicals, Irvine, CAl incorpora-
tion over the last 18 h [18]. In some experiments, freshly separated EC were 
stained with anti-CDla (Ortho), and fluorescence-activated cell sorting was 
performed to obtain separately CD1a+ and CD1a- EC. In other experi-
ments, before co-culture with CD4+ T lymphocytes, EC were preincubated 
for 30 min at 37 ' C with one of the following antibodies: LeuM5 (anti-
CDllc) (Becton Dickinson) (25 fLg/ml), anti-CDlc (Amac) (50 fLg/ml), 
mouse IgG2b (Pharmingen, San Diego, CAl (25 fLg/ml), and mouse IgG1 
(Sigma) (50 fLg/ml). 
For assessment of keratinocyte accessory antigen-presenting activity, 
CDla- fluorescence-activated cell sorter (FACS)-isolated EC were incu-
bated at various concentrations with gamma-irradiated JY B cells, an anti-
gen-presenting cell line, and allogeneic CD4+ T cells. 3H-Tdr uptake was 
then assessed at 7 d as above. 
RESULTS 
RA Upregulates Major Histocompatibility Complex (MHC) 
Class II Mean Fluorescence Intensity on Epidermal LC But 
Does Not Modify the Number ofHLA-DR+ or CDla+DR+ 
EC After 4 d of ifl vivo treatment with RA, the mean percentage of 
LC in RA-treated sites was not statistically different from the per-
centage of LC in vehicle-treated areas (Table I) . No evidence of 
interceUular adhesion molecule (ICAM+) cells, or DR-CD11c+, 
DR-CD1c+, or DR-CD36+ infiltrating cells was seen in any of the 
subjects (0% of total EC for each) (data not shown). To compare 
accurately the mean surface molecule density on a cell-per-cell basis 
for group comparisons from multiple individuals, we determined 
the FI of specific monoclonal antibody binding to cell subsets rela-
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Table I. In Vivo RA Treatment of Human Skin 
Does Not Modulate LC Numbers or Induce 
an Influx of Non-LC Leukocytes" 
Vehicle RA 
(% of Total EC) (% of Total EC) 
Total DR+ 2.4 ± 0.3% 2.1 ± 0.2% 
DR+CD1a+ 1.7 ± 0.2% 1.6 ± 0.2% 
DR+FcIgGRiI+ 2.0 ± 0.2% 1.7 ± 0.3% 
n 
5 
5 
4 
• Data expressed as mean percentage of total vehicle and RA-EC ± SEM of indicated 
number of subjects. Antigen-presenting cell subset infiltrations not induced by topical 
RA(O.l%). 
tive to isotype control binding [19,20). The group mean FI of anti-
HLA-DR on LC obtained from RA-treated sites (81.7 ± 9.3) (n = 
5) was almost twice the mean FI of anti-HLA-DR on vehicle LC 
(44.9 ± 6.7) (n = 5) (p < 0.02) (Table II). 
The class II MHC fluorescence increase was not associated with 
an increase in overall cell size because the LFLS of RA-EC was 
similar to that of vehicle EC; the mean ratio of RA-LC LFLS to 
vehicle LC LFLS was 1 .06 ± 0.05 light-scatter units. These data 
indicate that increased RA-LC class II MHC expression is due to an 
increase in class II MHC molecule density on LC. 
RA Specifically Upregulates CDlc, but Not CDla or CDlb 
Expression on LC Constitutive human LC expression of the 
dendritic antigen-presenting cell lineage markers CD1a, CD1b, 
and CD1c [17,18,21- 23] may be functionally important for T-cell 
activation [24,25). However, RA treatment exerted no effect on 
CD1a or CD1b expression by LC (vehicie-CD1a Fl, 220 ± 41.5 
versus RA-CDla Fl, 183 ± 38) (n = 5) (p> 0.3) (Table II) . By 
contrast, the mean Fl of anti-CD1c on RA-treated LC (4.9 ± 0.8) 
was slightly but consistently (four of five subjects tested) higher 
than the CD1c FI on vehicle-treated LC (3.2 ± 0.5) (p < 0.04) 
(n = 5) (Table II). 
Upregulation ofCDllc, but Not CDlla Or CDllb Expres-
sion On LC by RA The monocyte/macrophage CD11c (aXfJ2 
integrin) is also expressed 011 normal LC [17,26). In vivo retinoid 
treatment resulted in a consistent upregulation of CD11c expres-
sion on epidermal LC: CD11c-FI on RA-treated CD1a+DR+ LC 
(16.1 ± 4.4) was almost double that of CDllc-Fl on vehicle-
treated LC (9 ± 2.4) (p < 0 .03) (n = 5) (Table II). This upregula-
tion was selective for CD11c because RA did not induce de novo 
expression of CD11b (aM [32 integrin) and CDlla (LFA-1) (aLfJ2 
integrin) on freshly prepared epidermal LC (not shown). 
A representative experiment demonstrates raw data on LC 
CD11c and CD1a intensity (Fig 1). DR+ cells from vehicle-EC 
(panels A, B) and from RA-EC (panels C, D) were selected for 
second- and third-marker analysis. EC stained with anti- HLA-DR, 
Table II. Fluorescence Intensity Index of Human LC 
Molecules and Keratinocyte Class I MHC and ICAM 
Molecules After In Vivo RA Exposure" 
HLA-DR 
CLla 
CDle 
CDltc 
FcIgGRII 
On unfraetionated EC 
(96-98% keratinocytes) 
Class I MHC 
I CAM 
Vehicle 
(Mean FI ± SEM) 
44.9 ± 6.7 
220.0 ± 41.5 
3.2 ± 0.5 
9.0 ± 2.4 
20.5 ± 6.5 
106.0 ± 25.7 
1.0 ± 0.08 
RA 
(Mean FI ± SEM) 
81.7 ± 9.3b 
183.0 ± 38.1 
4.9 ±0.8' 
16.1±4.4J 
14.0 ± 5.0 
133.0 ± 30.7 
1,,1 ± 0.09 
n 
5 
5 
5 
5 
4 
5 
4 
• Data expressed as mean FI of specific antibodies on HLA-DR+ vehiclc-EC and 
RA-EC relative to isotype ± SEM of indicated l1umber of subjects. 
• p < 0.02. 
' p < 0.04. 
J P < 0.03. 
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in combination with FITC IgGl and PE IgG2b isotype controls, 
aJlowed cursors for defining positivity and negativity to be placed 
specifically according to LC nonspecific fluorescence, without in-
terference by keratinocyte fluorescence (Fig 1, left pallels). Upon 
combining FITC OKT6 and PE anti-CD11c with the APC anti-
DR, all DR+ cells moved from quadrant 3 to quadrant 2 (Fig 1, right 
panels), indicating positive expression of both CD1a and CD11c. In 
contrast to CDla intensity, which was unchanged, the mean chan-
nel PE (CD11c) fluorescence intensity of DR+ vehicle-EC was 
14.8, whereas the mean channel CD11c fluorescence of DR+ RA-
Ee was 42.3. 
By contrast to the modulation of CD 11 c and DR, the LC version 
of the FcIgGRII receptor (CD32) was not affected by retinoid ther-
apy (Table II). RA treatment did not induce ICAM and CD36 
expression on LC, or CD34, CD14, CD64, or CD1b (data not 
shown). RA also did not produce epidermotropism of cells bearing 
these surface markers (data not shown) . Keratinocytes did not mod-
ulate their expression of class I MHC (Table II), and ICAM was not 
induced on keratinocyte surfaces (data not shown). 
RA Upregulates EC Alloantigen Presentation But Does Not 
Induce Autoreactivity Incubation of CD4+ T cells with vehicle 
versus RA-EC revealed an increase in the allogeneic T-cell prolifer-
ation in response to RA-EC relative to vehicle-EC in each of the 
three subjects tested (Fig 2). The fold increase in cpm of RA-EC 
relative to vehicle-EC in each subject was 3.8, 2.6, and 3.2, respec-
tively. We next asked whether RA-induced upregulation ofLC was 
linked to induction of an autoreactive response, as occurs in diseased 
skin [18,27] or upon ill vitro culture of epidermal LC [27 - 29]. 
However, coculture of CD4+ T lymphocytes with either autolo-
gous vehicle- or RA-treated EC did not lead to T-cell proliferation 
(Fig 2, n = 2) . 
Purified RA-LC, and Not Keratinocytes, Are Responsible for 
Increased Epidermal Antigen-Presenting Activity Whereas 
both FACS-purified CDla- vehicle-EC and CDla- RA-EC were 
ineffective in inducing alloreactivity, increasing concentrations of 
purified CDla+ EC (2.5 X 103 to 20 X 103/ml) resulted in a dose-
dependent increase in antigen-presenting activity (Fig 3). In 
comparison to purified vehicle-LC, RA-CDla+ EC reproducibly 
displayed an increased activity at each antigen-presenting cell 
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Figure 1. Flow-cytometric analysis 
of electronically gated HLA-DR + EC 
expressed on two-parameter histo-
grams. Isotype controls: Mouse IgG I 
(FITC goat ami-mouse IgGl) and IgG2b 
(PE goat anti-mouse IgG2b) binding on 
HLA-DR+ vehicle-treated (upper/eft) and 
RA-treated (lolVer left) EC (representative 
experiment). DR+ vehicle EC (upper 
right, qlladrallts 2, 4) and DR+ RA-EC 
(lolVer right, quadrants 2, 4) subsets co-
express CDla (OKT6) and the ax fJ2 
integrin CDllc. Relative to CDllc+ 
DR+CDla+ vehicle EC (upper right. 
quadrant 2), the CD1Ic+DR+CDla+ 
RA-EC population is shifted to a higher 
CDllc intensity on the Y axis (lolVer 
right, quadrant 2). indicating a higher ex-
pression of the CDllc marker on DR+ 
RA-treated LC. 
concentration tested above 100 LC/well (mean fold increase = 
5.9 ± 2.1) (Fig 3, representative experiment). These data indicate 
that RA-LC are more potent in their antigen-presenting activity 
than vehicle-Ee. 
To determine whether upregulation of RA-EC antigen-present-
ing activity was due not only to LC upregulation, but also to modu-
lated keratinocytes. CD1a- RA-EC and CD1a- vehicle-EC were 
purified by FACS as above, and cultured with autologous CD4+ T 
cells and allogeneic B-antigen - presenting cells (JY B cell line). At 
this concentration, CDla- vehicle-EC exhibited little effect on an-
tigen-presenting activity (Fig 4), but CD la- RA-EC demonstrated 
a potent ability to inhibit alloantigen presentation (Fig 4). Thus, 
CD1a- FACS-purified RA-EC inhibited alloantigen presentation 
by the JY B cell line, indicating that elevated antigen-presenting 
activity of unfractionated RA-EC was not due to enhanced kerati-
nocyte accessory signals, but was due to upregulated LC antigen-
presenting activity alone. 
100 
80 
~ 
M 
6 60 
~ 
:E 40 Q, 
(,) 
20 
0 CD4+TC CD4+TC 
+ VEH-EC + RA-EC 
(AUTO) (AUTO) 
Figure 2. RA upregulates allogeneic CD4+T-cell (TC) proliferation 
induced by normal EC. Coculture of vehicle or RA-treated EC with 
autologolls CD4+ TC does not lead to auroreactiviry. Results represent the 
mean ± SEM cpm of[3H]Tdr uptake after 7 d culture of three (a11o) and two 
subjects (auto). 
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Figure 3. RA upregulates antigen-presenting cdl activity of puri-
fied epidermal LC. CDla+ and CDla- RA and vehIcle EC were sorted by 
FACS and cultured with allogeneic CD4+ T lymphocytes (50 X 103 per 
well). Purified LC derived from RA-EC displayed a markedly increased 
ability, relative to vehicle LC, to present antigen to T cells . Results are 
expressed as the mean ± SEM cpm of triplicate samples (n = 2). 
The fJ2 Integrin CDllc (p 150/95) is Critical for the Anti-
gen-Presenting Activity of Both Vehicle- and RA-Treated 
Epidermal LC To determine whether the upregulated CD1c 
and CD11c may, in addition to class II MHC, participate in the 
elevated RA-LC antigen-presenting activity, we performed block-
ing antibody studies. Preincubation of ex vi~o vehicle- or RA-treated 
EC with anti-CD11c (50 ,ug/ml) resulted In a blockade of allogen-
eic CD4+ T-cell responses (Fig 5), whereas incubation with mouse 
IgG2b isotype did not modify the upregulation of foreign alloanti-
gen presentation induced by retinoid treatment (Fig 5). By contrast, 
incubation with anti-CD1c, relative to its mouse IgG1 isotype con-
trol, had no effect on the allogeneic T-cell response (data not 
shown). 
DISCUSSION 
We have demonstrated a pharmacologic method that upregulates 
human antigen-presenting activity in vivo without concomitant in-
duction of autoreactivity. The upregulated antigen-presenting ac-
tivity of LC was associated with upregulated expression of class II 
MHC and CD11c. Class II MHC is critical for LC antigen presen-
tation [13], and its upregulation is known to be associated with 
upregulated antigen-~resenting activity [29]. We demonstrate here 
that CD11c (gp150j95) is also critical for LC antigen-presenting 
activity (Fig 5); its upregulation by RA (Fig 1, Table II) may thus 
25 
20 
....... 
b 15 .... 
~ 
~ 10 Q. 
0 
5 
0 JYB PLUS: 
+TC 
APC: JY B CELL LINE (2.5x1()3/wELL) 
TC: APe DEPLETED CD4+ 
KC: VEH va RA CD1a- EC 
VEH RA 
1 X 1()4 KC 
VEH RA 
2 X 1()4 KC 
Figure 4. Elevated whole RA-EC antigen-presenting activity is not 
due to enhanced keratinocyte accessory signals. CDta- RA- and vehi-
cle EC were sorted by FACS to obtain LC-depleted keratinocytes (KC) and 
cultured with allogeneic CD4+ T cells and 2.5 X 103 JY B cells. Data are 
expressed as mean ± SEM [3HJTdr uptake of triplicate samples at 7 d. 
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Figure 5. COllc expression on LC is critical for both normal and 
retinoid-modulated antigen-presenting activity. Preincubation of EC 
with anti-CDllc (50 Ilgjml) markedly inhibits, relative to IgG2b isotype, 
the alloantigen presentation of both vehicle and RA-EC to CD4+ T cells. 
Results are expressed as mean ± SEM [3HJTdr uptake at 7 d. 
also account for increased epidermal LC activity. CD11c (aX P2 
integrin) is expressed on normal LC [26] , on normal dermal LC 
[17], and on dendritic interdigitating cells in the lymph nodes [30] . 
Our results show that RA treatment markedly increases CD11c 
expression on LC and that this adhesion molecule plays a crucial 
role in antigen-presenting T-cell interactions (Fig 5) . 
The elevated capacity of purified RA-LC to activate T lympho-
cytes was not reflected in the keratinocyte population. LC-depleted 
EC were not able on their own to activate T cells (RA or vehicle) 
and, in fact, CD1a- RA-EC (keratinocytes) exhibited increased in-
hibitory effects on T-cell activation induced by the JY APC line. 
Retinoids may cause keratinocytes to release inhibitory soluble cy-
tokines, although topical RA treatment does not modify human 
epidermal interleukin-1 (IL-1) levels [31-33] or production of ara-
chidonic acid products such as the T-cell inhibitor prostaglandin E2 
[32]. Topical RA does, however, increase human epidermal trans-
forming growth factor-p levels [16,34], a potent inhibitor ofT-cell 
activation. The opposing effects of RA-treated keratinocytes versus 
RA-treated LC may account for the lack of induction of autostimu-
latory capacity of the RA-EC, despite upregulated LC ability to 
present alloantigen. 
Our in vivo results differ from the inhibition of epidermal anti-
gen-presenting activity by synthetic retinoids upon addition to an itl 
vitro co-culture of BC and allogeneic lymphocytes [35] . Although 
human cells were used in both cases, RA was not tested in the study 
of Dupuy et al. Retinoids can alter T-cell receptors for mitogens 
[4,36,37] or for IL-2 and thus also reduce proliferative responsive-
ness at the T -cell level [38 - 41]. 
Our study'S phenotypic and functional changes after in vivo RA 
treatment are to some extent similar to those observed after itl lIivo 
epicutaneous hapten sensitization in mice (i.e., increased I-A and I-E 
class II MHC expression) [42] and during the itl I/itro maturation of 
LC into potent dendritic cells (i.e., increased class II MHC and 
antigen-presenting activity) [28,43,44]. However, the effect of RA 
differs from the effect of in vitro culture on LC in that RA does not 
result in the reduced CD1a and FcIgGRII expression observed upon 
culture of LC and does not induce ICAM-1 or autoreactivity as 
occurs in cultured LC [43]. These differences indicate that RA does 
not induce a state of differentiation that represents maturation into 
dendritic antigen-presenting cells oflymphatics and regional nodes. 
RA-LC also differ from hyperstimulatory LC present in atopic der-
matitis and mycosis fungoides [18,45] in that RA-LC lack CD36 
and CD1b. These comparisons indicate that RA-LC represent a 
previously undescribed state of activation/differentiation of the 
human LC. 
In conclusion, ill vivo RA treatment of human skin results in an 
increased ability to present alloantigen to T cells, but not in a man-
ner that breaks the threshold for autoreactive responsiveness, per-
VOL. 103, NO.6 DECEMBER 1994 
haps because ?f a conc.omitant incr~ase in keratinocyte immunosup-
pressive activi ty. The IIlcreased actiVity appears related to changes 111 
surface-marker expression on LC such as HLA-DR and CDllc. 
Thus, we have demonstrated that in addition to class II MHC, 
CDllc is a molecule critically involved in T-cell activation by LC. 
The ability to upregulate cutaneous antigen-presenting function 
without modulating autoimmunity may be important in improving 
cutaneous immune responsiveness to microbial infections, vaccines, 
or tumor antigens. 
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